Browse News

Found 221 articles

• Kura Oncology Announces Late-Breaking Abstract Accepted for Oral Presentation at the 2023 European Hematology Association (EHA) Congress

  5/30/2023

  Kura Oncology, Inc. today announced that a late-breaking abstract with updated data from the Phase 1 trial of the Company’s menin inhibitor, ziftomenib, has been accepted for oral presentation at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany.

• Kura Oncology to Participate in Two Upcoming Investor Conferences - May 23, 2023

  5/23/2023

  Kura Oncology, Inc. today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences.

• Kura Oncology Reports First Quarter 2023 Financial Results

  5/10/2023

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported first quarter 2023 financial results and provided a corporate update.

• Kura Oncology to Participate in JMP Securities Life Sciences Conference

  5/9/2023

  Kura Oncology, Inc. today announced its participation in the JMP Securities Life Sciences Conference in New York.

• Kura Oncology to Report First Quarter 2023 Financial Results

  5/3/2023

  Kura Oncology, Inc. today announced that it will report first quarter 2023 financial results after the close of U.S. financial markets on Wednesday, May 10, 2023.

• Kura Oncology to Participate in Stifel Targeted Oncology Days

  4/18/2023

  Kura Oncology, Inc. today announced its participation in Stifel 2023 Targeted Oncology Days. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 1:00 p.m. ET / 10:00 a.m. PT on April 25, 2023.

• Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Farnesyl Transferase Inhibitor in Combination with Targeted Therapies

  4/17/2023

  Kura Oncology, Inc. today reported preclinical data supporting the potential use of farnesyl transferase inhibitors (FTIs) to treat various types of solid tumors in combination with targeted therapies, including KRASG12C inhibitors and anti-angiogenic tyrosine kinase inhibitors (TKIs).

• Kura Oncology Announces Acceptance of Two Abstracts for Presentation at AACR Annual Meeting

  3/14/2023

  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that two abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in Orlando from April 14-19, 2023.

• Kura Oncology to Participate in Upcoming Investor Conferences

  3/1/2023

  Kura Oncology, Inc. today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences.

• Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

  2/23/2023

  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported fourth quarter and full year 2022 financial results and provided a corporate update.

• Kura Oncology to Report Fourth Quarter and Full Year 2022 Financial Results

  2/16/2023

  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2022 financial results after U.S. financial markets close on Thursday, February 23, 2023.

• Kura Oncology Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia

  2/9/2023

  Kura Oncology, Inc. today announced that the first patients have been dosed in its KOMET-001 Phase 2 registration-directed trial of ziftomenib, the Company’s novel menin inhibitor, in patients with NPM1-mutant relapsed or refractory acute myeloid leukemia (AML).

• Kura Oncology to Participate in SVB Securities Global Biopharma Conference

  2/7/2023

  Kura Oncology, Inc. today announced its participation in the virtual SVB Securities Global Biopharma Conference.

• 

  Patient Death Pauses Another AML Trial

  1/26/2023

  Following the death of a patient, Magenta Therapeutics placed a hold on Phase I/II dose-escalation trial of its acute myeloid leukemia therapy.

• Kura Oncology Announces FDA Clearance of IND Application for KO-2806, a Next-Generation Farnesyl Transferase Inhibitor

  1/24/2023

  Kura Oncology, Inc. today announced the clearance by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for KO-2806, the Company's next-generation farnesyl transferase inhibitor (FTI), for the treatment of advanced solid tumors.

• Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting

  12/10/2022

  Kura Oncology, Inc. announced updated clinical data from KOMET-001, a Phase 1/2 trial of the Company’s potent and selective menin inhibitor, ziftomenib, including an encouraging safety and tolerability profile and clinical activity in patients with relapsed/refractory acute myeloid leukemia.

• Kura Oncology to Host Investor Event on December 10, 2022In-person event and live webcast to follow oral presentation of data from KOMET-001 at ASH in New Orleans

  12/1/2022

  Kura Oncology, Inc. today announced that it will host an investor event featuring members of the Kura management team and investigators from KOMET-001, a Phase 1/2 clinical trial of ziftomenib, the Company’s potent and selective menin inhibitor.

• Kura Oncology to Participate in Two Upcoming Investor Conferences - November 22, 2022

  11/22/2022

  Kura Oncology, Inc., announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences.

• Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million

  11/3/2022

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced a $25 million equity investment from Bristol Myers Squibb and a term loan facility with access to up to $125 million from Hercules Capital, Inc.

• Kura Oncology Reports Third Quarter 2022 Financial Results

  11/3/2022

  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported third quarter 2022 financial results and provided a corporate update.